The selection of a pan-AKT inhibitor assumes that all 3 AKT isoforms promote tumor formation and progression, however, data from this current study and other studies suggest that AKT1 and AKT2 have opposite effects on lung tumorigenesis. The gene discussed is AKT1; the disease is neoplasm.